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Maturation of activated B cells into Ig-secreting cellsis induced by T cell-derived
lymphokines that are able to induce B cell growth and/or differentiation (1). IL-5,
formerly called T cell-replacing factor (TRF) or B cell growth factor II (BCGFII),
has been shown to induce in vitro growth and differentiation of naturally activated
B cells, as well as murine chronic B cell leukemia (BCL1) cells (2-5), and to play
a major role in T cell-dependent IgA production in the murine system (6-10). We
and others (6, 8, 10) reported that IL-5 stimulates surface IgA+ (slgA+) B cells, but
not sIgA- B cells, giving rise to IgA-producing cells.
Transforming growth factor 0 (TGF0) was originally described by its ability to
confer anchorage-independent growth on nonmalignant fibroblasts, and is synthe-
sized and secreted by a variety of cells (11). Known effects on the immune system
include inhibition of lymphocyte proliferation, antibody production, and NK cell
function (12, 13). Here we will report that TGFR induces IgA production by LPS-
stimulated murine B cells as well as suppression of IgM and IgGl production.
Mice.
￿
BALB/c mice were purchased fromJapan SLC Inc., (Hamamatsu), and were main-
tained in the Laboratory Animal Facility of Kumamoto University.
CellLines.
￿
The chinese hamster ovary (CHO) cell line transfected with murine IL-5 cDNA
was provided by Dr. T. Nishihara (Suntory Central Research Laboratories, Osaka) and was
maintained in our laboratory.
Antibodies.
￿
TB13 rat IgG1 mAbs against mouse IL-5 were obtained as described (14). Rabbit
anti-mouse IgA and anti-IgGl antibodies were prepared as described (6). Purified anti-IgA
and IgGI antibodies were conjugated with horseradish peroxidase (HRPO) (CooperBiomed-
ical, Inc., Malvern, PA) according to the described methods (15). Goat anti-mouse IgM and
HRPO anti-mouse IgM antibodies were purchased from Zymed Laboratories (San Fran-
cisco, CA). Rabbit polyclonal antiTGF0 IgG antibody was obtained from R & D Systems,
Inc. (Minneapolis, MN). Affinity-purified goat anti-mouse IgA antibody was obtained from
Southern Biotechnology Associates Inc. (Birmingham, AL).
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Lymphokines.
￿
Human recombinant TGF,61 that had been previously described (16) was
a kind gift of Genentech Inc . (South San Francisco, CA) . IL-5 was purified from cultured
supernatant ofCHO cells as described (14) . The specific activity ofpurified IL-5 was 2.2 x
107 U/mg protein.
Antibody Production In Vitro .
￿
T cell-depleted B cells were prepared as described (6). To de-
plete sIgA' B cells, T cell-depleted splenicB cells were incubated for 1 h at room tempera-
ture on bacteriological grade petri dishes (Clinical Test Ware, SH90-20 ; Iwaki Glass Co . Ltd .,
Tokyo) that had been precoated with purified goat anti-mouse IgA antibody (6) . Cells nonad-
herent to the petri dishes were collected and used as sIgA- B cells . B cells thus obtained were
suspended inRPMI 1640medium (Sigma Chemical Company, St . Louis, MO) supplemented
with 5 x 10-5M 2-ME, penicillin (100 U/ml), streptomycin (100,ug/ml), and 10% FCS (855 ;
Flow Laboratories, Inc ., McLean, VA), and were cultured in a 96-well microplate (25860 ;
Corning Glass Works, Corning, NY) in the presence of 10 pg/ml LPS (Difco Laboratories
Inc ., Detroit, MI) . Recombinant cytokines were added 24 h after thecommencement ofthe
culture, as described (6) . The numbers of Ig-secreting cells were enumerated 5 d after the
initiation of the culture by reversed plaque-forming cells (PFC) assay (6) . For ELISA, cells
were cultured for 7 d .
ELISAMeasurement ofIg Production .
￿
ELISAs were done as described (15) . Goat anti-mouse
IgM antibody, rabbit anti-mouse IgGl antibody, and goat anti-mouse IgA antibody were
used for the solid phase antibody. HRPO anti-mouse IgA, HRPO anti-mouse IgM, orHRPO
anti-mouse IgGI antibody was used as the enzyme-linked antibody. o-Phenylenediamine and
hydrogen peroxide were used as substrates . Dilutions of the mouse reference serum (Miles
Scientific, Naperville, IL) were used to establish a standard curve .
Results
7GF-ft InducesIgA Production ofLPS-stimulatedB Cells.
￿
T cell-depletedB cells were
stimulated with LPS for 5 d, and TGF#, IL-5, or TGF0 plus IL-5 was added to
the culture on day 1 . As shown in Fig. 1, addition ofTGFfl or IL-5 enhanced IgA
PFC responses . IgA responses reached amaximal level when 1 ng/ml ofTGF/3 was
added, and were higher than those inducedby IL-5 . In this case, cell recoveries after
the culture with TGF# were decreased to-50% ofcontrol cultures (data not shown) .
Addition of both TGFS and IL-5 caused more striking IgA production than that
induced by either of cytokines . No significant IgA production was observed in the
absence of LPS.
To evaluate whetherTGF# selectively enhancesIgA production, the effect ofTGFJ6
on IgM and IgG1 production was also examined . As shown in Table I, addition
of IL-5enhanced IgA, IgM, and IgG1 production by LPS-stimulated B cells .TGF0
augmented IgA production and acted additively with IL-5, whereas it showed a
FIGURE 1 .
￿
Enhancement ofpolyclonal IgA
production of LPS-stimulated B cells by
TGFft . T cell-depleted B cells (105/well)
were stimulated with LPS (10 tcg/ml) for 5 d .
Either IL-5 (100 U/ml),TGF 16 (1 ng/ml), or
IL-5 plus TGFS was added on day 1 . After
the culture the numbers ofIgA-producing cells
were enumerated by the reversed PFC assay.
Results were expressed geometric means of
IgA PFC of triplicate cultures and SDs.SONODA ET AL.
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TABLE I
TGF-,B Enhances IgA Production by LPS-stimulated B Cells
T cell-depletecl B cells (105/well) were cultured with LPS (10 hg/ml) for 7 d. Either TGF-S,
IL-5 (100 U/ml), or TGF-0 plus IL-5 was added on day 1. After the culture IgA levels in su-
pernatants were titrated by ELISA. Results were expressed as mean value of triplicate cultures.
significant inhibitory effect on IgM and IgG1 secretion irrelevant to the existence
ofIL-5. The augmenting effect ofIgA production byTGFi0was abrogated by anti-
TGFS antibody (Table II), whereas IL-5-induced IgA synthesis was not affected.
Theseresults indicate that theeffect we are lookingat iscaused by TGF#, and TGF-0
is not involved in IL-5-mediated IgA production.
TABLE II
Effect ofAnti-TGF,6 Antibody on IgA Production
Anti-TGF-fl antibody or control antibody was added to the culture when TGF-0
or IL-5 was added on day 1 . Results were expressed mean value of triplicate
cultures.
We analyzed the time course ofTGFS and IL-5 for their additive effects on IgA
production. TGF-0 was added on day 2 or 3 to the culture in the presence of IL-5
(Fig. 2, groups 7 and 8). In other groups, IL-5 was added to the culture on day
2 or 3 (groups 5 and 6) in the presence ofTGFS . Either TGF13, IL-5, or TGFS
plus IL-5 was added to the culture on day 1 (groups 2-4). Simultaneous addition
ofTGF0 and IL-5 induced maximal IgA production (group 4). Addition of IL-5
onday2or3 inducedamaximum IgA productioninthe presence ofTGF-0(groups
5 and 6). In contrast, addition ofTGFS on day 2 or 3 showed no additive effect
by antecedent addition of IL-5 (groups 7 and 8).
7GF--0 Acts on sIgA- B Cellsto Induce IgA Production.
￿
sIgA- B cells were separated
Stimulant
TGF-0
ng/ml
IL-5
U/ml
Anti-TGF-0
pg/ml
IgA antibody
production
nglml
0 0 0 84
1 0 0 480
1 0 25 88
0 100 0 286
0 100 25 265
TGF-0 (-) IL-5
IgA
(+) IL-5
IgM
(-) IL-5 (+) IL-5
IgG
(-) IL-5
1
(+) IL-5
nglml
0 84 440 25,000 56,000 640 740
100 290 752 ND ND ND ND
10 440 926 5,160 12,400 48 52
1 448 1,580 11,800 24,400 120 76
0.1 170 1,180 18,400 36,400 360 270
0.01 92 320 ND ND ND ND1418
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from sIgA+ B cells as described in Materials and Methods . Contamination of sIgA+
B cells in the sIgA- B cell population was <0.5% . Because sIgA+ B cells thus ob-
tained were not enough to carry out further analysis, either unfractionated or sIgA-
B cells were cultured with LPS and cytokines to be tested . IgA production was ob-
served even when sIgA- B cells were cultured with TGF) (Table III) and its level
was comparable with that observed in the culture of unfractionatedB cells withTGF0 .
However, sIgA- B cells did not differentiate into IgA-producing cells in response
to IL-5 . IL-5 showed an additive effect withTGF0 on IgA production by sIgA-
B cells, whereas both IgM and IgG1 production induced by IL-5 were inhibited
by TGFS, and there were few differences between the unfractionated and sIgA-
B cells regarding their production (data not shown) .
TABLE III
FIGURE 2 .
￿
Kinetic analysis of synergy be-
tween TGF0 and IL-5 . T cell-depleted
splenic B cells were cultured with LPS as de-
scribed in Fig . 1 . TGFS (1 ng/ml) or IL-5 (100
U/ml) was added to the culture as indicated .
(0) Time period during which TGF-0 was
present ; (®) period during which IL-5 was
present .
sIgA- B Cells Responded to TGF,d in the Presence of LPS
Either unfractionated or sIgA" B cells (105/well) were stimulated with LPS (10
ltglml) for 7 d . Either TGF-S, IL-5, or TGF-0 plus IL-5 was added on day 1
ofthe culture . After the culture IgA levels in cultured supernatants were deter-
mined by ELISA . Results were expressed as mean of triplicate cultures .
Discussion
This paperdocuments the effects ofTGFI# on IgA production . TGF /3 selectively
enhanced polyclonal IgA formation of LPS-stimulated B cells and acted additively
with IL-5 forIgA production only whenTGFSwasadded to the culture simultane-
ously with IL-5 or before IL-5 (Figs . i and 2, and Tables I and II) . More interest-
ingly, sIgA B cells responded to TGFR, resulting in IgA-secreting cells (Table III),
IgA produced by B cells
Stimulant Unfractionated sIgA -
TGF-/3
ng/ml
IL-5
U/ml
Exp . 1 Exp . 2 Exp. 1
ng/ml
Exp . 2
0 0 64 46 <20 <20
10 0 ND 220 ND 210
1 0 246 184 690 220
0 100 160 110 52 <20
1 100 890 435 1,320 560SONODA ET AL.
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whereas IL-5 was ineffective. Several investigators, including us (6-10), demonstrated
that IL-5 enhances IgA formation by LPS-stimulated B cells. As we reported, IL-5
can stimulate DNP-primed sIgA' B cells for anti-DNP IgA antibody production
(6). It is also evident from Table III that LPS-stimulated sIgA- B cells do not re-
spond to IL-5. These results suggest that IL-5 predominantly acts on sIgA+ but not
sIgA- B cells as a maturation factor for IgA production. Taking in account the fact
that IL-5 induces IgM and IgGI production and TGFS inhibits this production,
TGFSenhances IgA formation by different mechanisms than those mediated by IL-5.
There are at least two possibilities to account for the enhancing effect of TGFS
on IgA production. First, TGFS may expand sIgA- B cells to switch to sIgA' B
cells. In this case, TGFS can be thought of as an IgA-specific class-switching factor.
Alternatively, TGFS may simply be expanding a specific subset ofB cellsor B cells
at a particular stage of differentiation that are already programmed to switch to IgA.
The fact that TGFS was effective in enhancing IgA formation in sIgA- B cells
(Table III) may support the idea that the enhancement of IgA formation by TGFS
is caused by expansion of B cells switching from sIgA - to sIgA+ and also by post-
switched B cells at a particularstage ofdifferentiation and by induction of differenti-
ation of these cells to IgA-forming cells. Kawanishi et al. (17) reported that T cells
in Peyer's patches, but not in spleen, induce LPS-stimulated IgM-bearing B cells
to switch to sIgA' B cells. TGFS may be one of the candidates for such an IgA-
switching factor, however, it is not well characterized concerningTGFS-producing
T cell subsets. If TGFS could be produced by the same T cell subset that produces
IL-5, sequential stimulation of T cellsby microbial antigen may induce preferential
production of TGFS and IL-5, which in turn induces sIgA- B cells to sIgA' B cells
followed by differentiation into IgA-secreting cells.
In conclusion, although TGFS inhibits B cell proliferation, it selectively induces
IgA production by sIgA' B cells as well as suppresses IgM and IgGI production,
and TGFS acts on B cellsadditively with IL-5 for IgA production. The experimental
system described here should prove to be very useful in further analysis of the steps
involved in T cell-dependent IgA production of murine B cells.
Summary
Effects of transforming growth factor # (TGFS) on IgA production by LPS-
stimulated B cells have been studied. TGFS itself could augment polyclonal IgA
productionin concomitant inhibitionofpolyclonal IgM and IgG1 production. Fur-
thermore, TGFS and IL-5 additively augmented IgA production. TGFS exerted
its activity early in the culture (by 2 d in a 5-d culture) and IL-5 was required late
in the culture. Surface IgA' (sIgA-) B cells responded to TGFS for the develop-
ment of IgA-secreting cells. By contrast, sIgA' B cells, but not sIgA- B cells,
responded to IL-5 for IgA production. These results suggest that TGFShas a differen-
tial role in the induction of IgA production from IL-5 on murine-activated B cells.
We thank Dr. T Nishihara and Genetech Inc., South San Francisco, CA, for providing IL-5-
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